Sonoma Pharmaceuticals (SNOA) Stock Statistics & Valuation Metrics

Sonoma Pharmaceuticals has a market cap or net worth of $5.36M. The enterprise value is $432.97K.

Sonoma Pharmaceuticals has 4,785,801 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sonoma Pharmaceuticals’s return on equity (ROE) is -1.03 and return on invested capital (ROIC) is -24.05%.

The current PE Ratio of Sonoma Pharmaceuticals is ―. Sonoma Pharmaceuticals’s PEG ratio is 0.03.

In the last 12 months, Sonoma Pharmaceuticals had revenue of 19.53M and earned -3.17M in profits. Earnings per share was -1.89.

In the last 12 months, operating cash flow was -3.39M and capital expenditures -229.00K, giving a free cash flow of -3.62M billion.

Sonoma Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Sonoma Pharmaceuticals upcoming earnings date is Aug 6, 2026, After Close (Confirmed).

Sonoma Pharmaceuticals as a current ratio of 2.50, with Debt / Equity ratio of 27.21%

In the past 12 months, Sonoma Pharmaceuticals has paid -244.00K in taxes.

Sonoma Pharmaceuticals EV to EBITDA ratio is -0.87, with an EV/FCF ratio of -0.49.

Sonoma Pharmaceuticals has $2.40M in cash and marketable securities with $842.00K in debt, giving a net cash position of $1.56M billion.

Gross margin is 37.97%, with operating margin of -12.60%, and net profit margin of -16.26%.

The average price target for Sonoma Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―